MENU
Go to the list of all blogs
Anna G's Avatar
published in Blogs
Oct 31, 2022

AbbVie (ABBV, $145.47) beats Q3 expectations, despite revenue miss

AbbVie Inc. ‘s third quarter earnings came in at $3.66 per share for the third quarter of 2022 (up +29.3% from the year-ago quarter), exceeding the Zacks Consensus Estimate of $3.56 per share.

Revenues rose +3.3% year-over-year to $14.81 billion, missing the Zacks Consensus Estimate of $14.92 billion.

In immunology, AbbVie’s flagship drug Humira experienced a 3.9% sales growth to $5.56 billion on an operational basis. Sales in the U.S. grew +7.4% to $4.96 billion, vs. the -16.8% decline in ex-U.S. market sales.

AbbVie narrowed the full-year 2022 adjusted earnings per share guidance range to $13.84-$13.88, from the prior guidance of $13.78-$13.98. The Zacks Consensus Estimate is $13.89 per share.

Related Ticker: ABBV

ABBV's Indicator enters downward trend

The Aroon Indicator for ABBV entered a downward trend on November 11, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 94 similar instances where the Aroon Indicator formed such a pattern. In of the 94 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABBV's RSI Oscillator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 12, 2025. You may want to consider a long position or call options on ABBV as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on November 12, 2025. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

ABBV moved above its 50-day moving average on November 11, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABBV crossed bullishly above the 50-day moving average on November 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in of 369 cases, the price rose further within the following month. The odds of a continued upward trend are .

ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (8.944). ABBV's P/E Ratio (179.000) is considerably higher than the industry average of (24.214). Projected Growth (PEG Ratio) (0.423) is also within normal values, averaging (2.072). Dividend Yield (0.028) settles around the average of (0.026) among similar stocks. ABBV's P/S Ratio (7.022) is slightly higher than the industry average of (3.671).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 100.21B. The market cap for tickers in the group ranges from 72.83K to 948.45B. LLY holds the highest valuation in this group at 948.45B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 19%. SCLX experienced the highest price growth at 25%, while MAYNF experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was 56% and the average quarterly volume growth was 88%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 60
Price Growth Rating: 51
SMR Rating: 63
Profit Risk Rating: 74
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
ABBV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ABBV showed earnings on October 31, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
50000
Web
http://www.abbvieinvestor.com
Interact to see
Advertisement
On May 16, 2025, Moody's Ratings downgraded the United States' sovereign credit rating from its pristine AAA to Aa1, citing concerns over the nation's ballooning $36 trillion debt.
#trading
Tickeron, Inc., a leading provider of AI-driven trading tools, is thrilled to announce the launch of its token on the innovative Believe App, a platform revolutionizing community-driven funding.
#trading
Discover how AI-powered Dual Agent Trading Bots are transforming emotional trading into data-driven strategy. From mastering fear and greed to using inverse ETFs and pattern recognition, this article reveals how Tickeron's Agentic AI enables smarter, adaptive market moves.
#trading
Walmart’s stock is up nearly 54% in 2025, fueled by strong earnings, e-commerce growth, and investor confidence. This article explores Walmart’s financials, AI-driven analysis tools from Tickeron, and how traders are navigating market volatility with WMT.
#trading
Alphabet Inc. (GOOG, GOOGL), the parent company of Google, today released a financial update highlighting its performance and strategic initiatives as it approaches its Q2 2025 earnings report on July 29.
A routine Treasury bond auction shook markets on May 21, 2025, triggering an 80-point S&P 500 plunge as yields spiked above 5%. Explore what caused the sudden drop, how macroeconomic pressures played a role, and how Tickeron’s AI trading bots capitalized on the chaos.
#investment#trading
Ethereum ($ETH) is nearing a potential breakout above $4,000 as its 3-day chart forms a bullish Descending Broadening Wedge. With AI trading tools like Tickeron’s proven agents, traders are watching closely for a move that could define the next major crypto trend.
Bitcoin has officially hit $109,000 on May 21, 2025—exactly as predicted by Tickeron’s AI nearly two months ago. This milestone validates the platform’s AI accuracy and highlights how traders can use Tickeron’s AI Double Agents to navigate crypto market volatility with confidence.
Ethereum (ETH) is capturing the attention of traders and analysts alike, with its 3-day chart forming a Descending Broadening Wedge pattern—a classic technical setup that often precedes significant price movements.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading tools, shared a bold prediction on X.com about Bitcoin’s (BTC) price trajectory.
#artificial_intelligence#trading
A turbulent week rocked global markets as the S&P 500 slid 3% following a U.S. credit downgrade, while Bitcoin surged past $111K and gold soared. Strong UK inflation and retail sales data added to the volatility, highlighting growing concerns over global economic stability.
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#investment#artificial_intelligence
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#artificial_intelligence#trading
Tickeron, a leader in AI-powered financial solutions, proudly announces the launch of its Double Agent Trading Bot, designed for trading Carpenter Technology Corporation (CRS) and Direxion Daily Semiconductor Bear 3x Shares (SOXS).
#artificial_intelligence
Apple Inc. (AAPL), a global leader in consumer electronics, continues to be a cornerstone of the technology sector, driving innovation and commanding significant market attention.
#artificial_intelligence
NVIDIA’s earnings on May 28 could jolt the tech sector. With market volatility rising, traders are turning to Tickeron’s AI Agent for real-time insights, predictive analytics, and dual-strategy trading tools to navigate potential price swings and seize market opportunities.
#artificial_intelligence
As the DOJ and FTC move to break up Google’s search dominance and impose AI investment oversight, the tech giant faces a pivotal legal battle that could reshape the digital and AI landscapes—creating major implications for investors, competitors, and consumers alike.
#artificial_intelligence
GameStop (GME) continues to captivate investors with its explosive volatility and strong retail sentiment. As AI tools highlight bullish signals and a possible breakout, traders weigh the risks of speculation against the potential rewards in May 2025.
#artificial_intelligence
Mastercard (MA) continues to impress investors with strong earnings, rising digital payments, and bullish AI-driven signals. Backed by robust financials and cutting-edge trading tools from Tickeron, MA stands out as a leader in the fintech space for 2025.